Table 3.
Selected RSV vaccines under clinical development
| Inhibitors | Target | Mechanism of action | Clinical status | Clinical trials |
|---|---|---|---|---|
| GS-5806 (Presatovir) | F protein | Targets the RSV F protein to inhibit the entry of the virus | Phase 2b | NCT02254421; EudraCT, #2014-002475-29 |
| JNJ-53718678 | Targets the RSV F protein to inhibit the entry of the virus | Phase 1b/2 | NCT02593851; NCT03656510; NCT04056611 | |
| AK0529 (Ziresovir, RO-0529) | Targets the RSV F protein to inhibit the entry of the virus | Phase 2/3 | NCT03699202; NCT04231968 | |
| RV521 | Targets the RSV F protein to inhibit the entry of the virus | Phase 2a | NCT03258502 | |
| RSV604 | N protein | Inhibits the interaction between the virus and host proteins that facilitate RSV604 binding of the N protein to block effective viral transcription. | Phase 1 | NCT00416442 |
| EDP-938 | Targets binding of viral N protein to block RSV replication in the postreplication phase | Phase 2 | NCT04816721 | |
| ALN-RSV01 | RNA | Targets RSV N transcripts by forming an RNA-induced silencing complex to inhibit translation | Phase 2b | NCT01065935; NCT00658086 |
| lumicitabine (ALS-8176) | Polymerase L | Targets RSV polymerase complex, causing chain termination of RNA synthesis | Phase 2a | NCT02673476 |
| AZ-27 | Inhibits the initiation of RNA synthesis from the promoter | Preclinical | Null | |
| PC786 | Interrupts RSV L-protein polymerase activity | Phase 1/2 | NCT03382431 | |
| JNJ-64417184 | Interrupts RSV L-protein polymerase activity | Phase 1 | NCT04121052; NCT04258189 |
Sources: ClinicalTrials.gov and clinicaltrialsregister.eu.